| 摘要 |
FIELD: pharmachology ^ SUBSTANCE: invention refers to the RSV-replication inhibitors with formula (I) Its additive salts and stereochemically isomeric forms where Q means hydroxy, C1-4alkyloxy, C1-4alkylcarbonylamino, C1-4alkyloxycarbonylamino, carboxyl, C1-4alkyloxycarbonyl, C1-4alkylcarbonyl, aminocarbonyl, mono- or di(C1-4alkyl)aminocarbonyl; each Alk is C1-6alkandiyl; R1 means heterocycle chosen out of pyridyl, pyrazynil, pirydazynil, pyrimidinyl and pyrrolyl; where each of stated heterocycles optionally can be substituted with 1, 2 or 3 substitutes, each of which is independently chosen out of group including hydroxyl, C1-6alkyl and hydroxyC1-6alkyl; R2 means hydrogen atom; R3 means hydrogen atom; R4 means Ar2; Ar2 means phenyl substituted with one or several substitutes i.e. 2, 3, 4 or 5 chosen out of halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, N(R5aR5b)-sulphonyl, R5b-O-C1-6-alkyl, Het, Het-C1-6alkyl, where Het means morhpolynyl, N(R5aR5b)- C1-6-alkyl, N(R5aR5b)-C(=O)-C1-6-alkyl; R5a means hydrogen atom; R5b means hydrogen atom, and also refers to pharmaceutical compositions containing compounds (I) and methods of production of compounds (I). ^ EFFECT: improved production of medicine. ^ 8 cl, 4 ex, 1 tbl |
